p.86 抽出テキスト

355. Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA 2018;320:2221–2230. https:// doi.org/10.1001/jama.2018.17242 356. Niu Q, Wang Z, Zhang Y, Wang J, Zhang P, Wang C, et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Therap 2017;22:142–152. https://doi.org/10.1177/1074248416663647 357. Yang R, Xu H, Pedersen NL, Li X, Yu J, Bao C, et al. A healthy lifestyle mitigates the risk of heart disease related to type 2 diabetes: a prospective nested case-control study in a nationwide Swedish twin cohort. Diabetologia 2021;64:530–539. https://doi.org/10. 1007/s00125-020-05324-z 358. Mancini GJ, Maron DJ, Hartigan PM, Spertus JA, Kostuk WJ, Berman DS, et al. Lifestyle, glycosylated hemoglobin A1c, and survival among patients with stable ischemic heart disease and diabetes. J Am College Cardiol 2019;73:2049–2058. https://doi.org/10.1016/ j.jacc.2018.11.067 359. Magliano DJ, Chen L, Carstensen B, Gregg EW, Pavkov ME, Salim A, et al. Trends in all-cause mortality among people with diagnosed diabetes in high-income settings: a multicountry analysis of aggregate data. Lancet Diabetes Endocrinol 2022;10: 112–119. https://doi.org/10.1016/S2213-8587(21)00327-2 360. Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson A-M, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2018;379:633–644. https://doi.org/10.1056/NEJMoa1800256 361. Gæde P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580–591. https://doi. org/10.1056/NEJMoa0706245 362. Oellgaard J, Gæde P, Rossing P, Rørth R, Køber L, Parving H-H, et al. Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. Diabetologia 2018;61:1724–1733. https://doi.org/10.1007/s00125-018-4642-y 363. Gæde P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving H-H, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016;59:2298–2307. https://doi.org/10.1007/s00125-016-4065-6 364. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbæk A, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a clusterrandomised trial. Lancet 2011;378:156–167. https://doi.org/10.1016/S0140-6736(11) 60698-3 365. Griffin SJ, Rutten GE, Khunti K, Witte DR, Lauritzen T, Sharp SJ, et al. Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial. Lancet Diabetes Endocrinol 2019;7:925–937. https://doi.org/10.1016/S2213-8587(19) 30349-3 366. Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 2017;5:951–964. https://doi.org/10.1016/S2213-8587(17)30327-3 367. Ferrannini G, De Bacquer D, De Backer G, Kotseva K, Mellbin L, Wood D, et al. Screening for glucose perturbations and risk factor management in dysglycemic patients with coronary artery disease—a persistent challenge in need of substantial improvement: a report from ESC EORP EUROASPIRE V. Diabetes Care 2020;43: 726–733. https://doi.org/10.2337/dc19-2165 368. Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. Polypill strategy in secondary cardiovascular prevention. N Engl J Med 2022;387: 967–977. https://doi.org/10.1056/NEJMoa2208275 369. Cersosimo E, Johnson EL, Chovanes C, Skolnik N. Initiating therapy in patients newly diagnosed with type 2 diabetes: combination therapy vs a stepwise approach. Diabetes Obes Metab 2018;20:497–507. https://doi.org/10.1111/dom.13108 370. Rodbard HW, Visco VE, Andersen H, Hiort LC, Shu DH. Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial. Lancet Diabetes Endocrinol 2014;2:30–37. https://doi.org/10.1016/S2213-8587(13)70090-1 371. Balducci S, D’Errico V, Haxhi J, Sacchetti M, Orlando G, Cardelli P, et al. Effect of a behavioral intervention strategy on sustained change in physical activity and sedentary behavior in patients with type 2 diabetes: the IDES_2 randomized clinical trial. JAMA 2019; 321:880–890. https://doi.org/0.1001/jama.2019.0922 372. Astin F, Lucock M, Jennings CS. Heart and mind: behavioural cardiology demystified for the clinician. Heart 2019;105:881–888. https://doi.org/10.1136/heartjnl-2016-310750 373. Zulman DM, Haverfield MC, Shaw JG, Brown-Johnson CG, Schwartz R, Tierney AA, et al. Practices to foster physician presence and connection with patients in the clinical encounter. JAMA 2020;323:70–81. https://doi.org/10.1001/jama.2019.19003 374. Miller WR, Rose GS. Toward a theory of motivational interviewing. Am Psychol 2009; 64:527. https://doi.org/10.1037/a0016830 375. Kim J, Hur M-H. The effects of dietary education interventions on individuals with type 2 diabetes: a systematic review and meta-analysis. Int J Environ Res Public Health 2021; 18:8439. https://doi.org/10.3390/ijerph18168439 376. Hennein R, Hwang SJ, Au R, Levy D, Muntner P, Fox CS, et al. Barriers to medication adherence and links to cardiovascular disease risk factor control: the Framingham Heart Study. Intern Med J 2018;48:414–421. https://doi.org/10.1111/imj.13687 377. Goldstein CM, Gathright EC, Garcia S. Relationship between depression and medication adherence in cardiovascular disease: the perfect challenge for the integrated care team. Patient Prefer Adherence 2017;11:547–559. https://doi.org/10.2147/PPA. S127277 378. Palmer MJ, Machiyama K, Woodd S, Gubijev A, Barnard S, Russell S, et al. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults. Cochrane Database Syst Rev 2021;3:CD012675. https://doi.org/10.1002/14651858.CD012675.pub3 379. Dobson R, Whittaker R, Jiang Y, Maddison R, Shepherd M, McNamara C, et al. Effectiveness of text message based, diabetes self management support programme (SMS4BG): two arm, parallel randomised controlled trial. BMJ 2018;361:k1959. https://doi.org/10.1136/bmj.k1959 380. Wändell PE, de Waard A-KM, Holzmann MJ, Gornitzki C, Lionis C, de Wit N, et al. Barriers and facilitators among health professionals in primary care to prevention of cardiometabolic diseases: a systematic review. Family Practice 2018;35:383–398. https://doi.org/10.1093/fampra/cmx137 381. Krempf M, Parhofer KG, Steg PG, Bhatt DL, Ohman EM, Röther J, et al. Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol 2010;105:667–671. https://doi.org/10.1016/j. amjcard.2009.10.048 382. BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503–2515. https://doi.org/10.1056/ NEJMoa0805796 383. Krishnaswami A, Hardison R, Nesto RW, Sobel B, BARI 2D Investigators. Presentation in patients with angiographically documented coronary artery disease and type II diabetes mellitus (from the BARI 2D Clinical Trial). Am J Cardiol 2012;109:36–41. https:// doi.org/10.1016/j.amjcard.2011.08.004 384. Anand DV, Lim E, Hopkins D, Corder R, Shaw LJ, Sharp P, et al. Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J 2006;27:713–721. https://doi.org/10.1093/eurheartj/ehi808 385. Goraya TY, Leibson CL, Palumbo PJ, Weston SA, Killian JM, Pfeifer EA, et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am College Cardiol 2002;40:946–953. https://doi.org/10.1016/s0735-1097(02)02065-x 386. Lièvre MM, Moulin P, Thivolet C, Rodier M, Rigalleau V, Penfornis A, et al. Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening. Trials 2011;12:23. https://doi.org/10.1186/1745-6215-12-23 387. Muhlestein JB, Lappé DL, Lima JA, Rosen BD, May HT, Knight S, et al. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. JAMA 2014; 312:2234–2243. https://doi.org/10.1001/jama.2014.15825 388. Young LH, Frans JT, Chyun DA, Davey JA, Barrett EJ, Taillefer R, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009;301: 1547–1555. https://doi.org/10.1001/jama.2009.476 389. Clerc OF, Fuchs TA, Stehli J, Benz DC, Gräni C, Messerli M, et al. Non-invasive screening for coronary artery disease in asymptomatic diabetic patients: a systematic review and meta-analysis of randomised controlled trials. Eur Heart J Cardiovasc Imaging 2018; 19:838–846. https://doi.org/10.1093/ehjci/jey014 390. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004;292:2227–2236. https://doi.org/10. 1001/jama.292.18.2227 391. Schmidt AC, Graf C, Brixius K, Scholze J. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus. Clin Drug Invest 2007;27:841–849. https://doi.org/10.2165/00044011-200727120-00006 392. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007;100:1254–1262. https://doi.org/10.1016/j.amjcard. 2007.05.057 393. Arnold SV, McGuire DK, Spertus JA, Li Y, Yue P, Ben-Yehuda O, et al. Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c. Am Heart J 2014;168:457–465.e2. https://doi.org/10. 1016/j.ahj.2014.06.020 394. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006;27:42–48. https:// doi.org/10.1093/eurheartj/ehi495 Downloaded from academic.oup.com/eurheartj/article/44/39/4043/7238227 by guest on 07 October 2026